South Korea’s BiocurePharm To Produce Biosimilars In Thailand
This article was originally published in PharmAsia News
SEOUL - South Korean biopharmaceutical company BiocurePharm signed a memorandum of understanding with Thailand pharmaceutical distributor Kwang Tiang Dispensary to build a $20 million plant in Thailand to produce five types of biosimilar products for anemia and hepatitis, BiocurePharma announced Nov. 13
You may also be interested in...
OSONG, South Korea - Venture capitalists are seeing the biggest returns from technology platforms or single-project financing, Hui-Hsing Ma, venture partner with TVM Capital told Bio Korea attendees.
Asia Partnerships Critical To Big Pharma’s Drying Pipelines, Merck Exec Tells Bio Korea (Part 2 of 2)
[Editor's note: This is part two of a two-part story from Bio Korea; part one was published in PharmAsia News, Oct. 12, 2008.]
SHANGHAI - Fresh safety concerns could be raised over the use of biosimilar erythropoietin stimulating agents after a patient in Thailand, who received an epoetin alfa biosimilar, developed ESA-related pure red cell aplasia, according to Baird analyst Christopher Raymond